Relay Therapeutics, Inc. RLAY R2KR3KPHARMA
Company Overview
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $15.36M (+53.4% YoY); net profit $-276.48M.
- Trailing 12 Months Year-on-year growth — revenue -60.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -28.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -28.58% |
| 1 Year: | -60.90% |
Stock Price Performance
| 1 Year: | +456.73% |
| 6 Months: | +92.52% |
| 3 Months: | +40.83% |
| 1 Month: | -3.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -28.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RLAY Relay Therapeutics, Inc. R2KR3KPHARMA | 19.04 | -12.21 | $4.17B | 0.00% | -50.82% | -40.01% | -28.58% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 952.00K | 844.00K | 666.00K | 419.00K | 365.00K | 344.00K | 226.00K | 119.00K | 25.20M | 10.01M | 0 | 0 | 7.68M | 677.00K | 0 | 3.00M | 350.00K |
| Operating Income | - | -19.91M | -21.91M | -26.46M | -27.72M | -36.61M | -42.41M | -193.58M | -60.99M | -62.72M | -77.81M | -85.89M | -101.18M | -106.05M | -73.58M | -90.36M | -100.76M | -96.37M | -84.87M | -76.85M | -80.39M | -78.59M | -90.82M |
| Net Income | -14.18M | -17.54M | -19.67M | -24.89M | -26.72M | -36.08M | -42.18M | -193.40M | -60.83M | -62.05M | -76.79M | -84.17M | -94.24M | -98.50M | -65.73M | -81.39M | -92.21M | -88.11M | -77.06M | -70.38M | -74.15M | -73.29M | -83.71M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.66 | -0.57 | -0.71 | -0.76 | -0.78 | -0.81 | -0.54 | -0.62 | -0.69 | -0.63 | -0.46 | -0.41 | -0.43 | -0.41 | -0.41 |
| R&D Expense | - | 16.40M | 18.26M | 21.70M | 21.67M | 24.38M | 30.62M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 82.65M | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M |
| Operating Income | -84.05M | -55.80M | -364.70M | -299.27M | -373.00M | -372.47M | -302.74M |
| Net Income | -75.31M | -52.41M | -363.87M | -290.51M | -341.97M | -337.71M | -276.48M |
| Diluted EPS | - | -5.40 | -3.82 | -2.59 | -2.79 | -2.36 | -1.61 |
| R&D Expense | 70.31M | 99.86M | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 393.07M | 799.83M | 1.01B | 1.10B | 843.98M | 871.30M | 621.33M |
| Total Equity | -110.93M | -180.44M | 763.29M | 897.81M | 950.22M | 752.00M | 777.79M | 567.06M |
| Cash & Equivalents | - | 41.95M | 447.65M | 280.12M | 151.79M | 143.74M | 124.29M | 84.02M |
| Total Liabilities | - | 35.73M | 36.54M | 110.64M | 149.55M | 91.98M | 93.50M | 54.27M |
| Current Liabilities | - | 11.99M | 13.63M | 24.32M | 63.71M | 30.27M | 50.73M | 25.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -66.13M | -102.49M | -74.41M | -229.49M | -300.32M | -249.11M | -235.46M |
| Investing Cash Flow | -319.02M | 81.67M | -479.51M | -188.75M | 257.63M | -41.08M | 192.80M |
| Financing Cash Flow | 5.61M | 426.51M | 388.09M | 289.91M | 34.75M | 270.15M | 1.60M |
| Capital Expenditure | -8.00M | -1.93M | -3.47M | -9.06M | -4.13M | -2.02M | -410.00K |
| Free Cash Flow | -74.14M | -104.42M | -77.88M | -238.55M | -304.44M | -251.12M | -235.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | -67.5% | -12,040.2% | -21,670.9% | -1,460.1% | -3,722.1% | -1,971.6% |
| Net Margin % | - | -63.4% | -12,012.9% | -21,036.1% | -1,338.7% | -3,374.7% | -1,800.6% |
| ROE % | 41.7% | -6.9% | -40.5% | -30.6% | -45.5% | -43.4% | -48.8% |
| ROCE % | -22.1% | -7.1% | -37.1% | -28.9% | -45.8% | -45.4% | -50.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SB Investment Advisers (UK) LTD | 12.73% | 27.90M | $523.78M |
| 2 | FMR, LLC | 9.18% | 20.11M | $377.47M |
| 3 | Casdin Capital, LLC | 7.32% | 16.04M | $300.98M |
| 4 | Blackrock Inc. | 6.98% | 15.29M | $286.96M |
| 5 | Perceptive Advisors Llc | 6.44% | 14.11M | $264.77M |
| 6 | Commodore Capital Lp | 5.48% | 12.00M | $225.24M |
| 7 | State Street Corporation | 4.62% | 10.13M | $190.05M |
| 8 | Vanguard Capital Management LLC | 4.09% | 8.96M | $168.26M |
| 9 | Price (T.Rowe) Associates Inc | 3.52% | 7.71M | $144.69M |
| 10 | Nextech Invest, Ltd. | 3.09% | 6.78M | $127.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RLAY
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and gen…
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near a new 3-year high. Technical momentum i…
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clinic…
RLAY — Frequently Asked Questions
What is the current share price of Relay Therapeutics, Inc. (RLAY)?
As of 2026-09-07 16:24 PDT, Relay Therapeutics, Inc. (RLAY) trades at $19.04 on NasdaqGM. Its 52-week range is $3.39 to $20.75.
What is the market capitalisation of RLAY?
Relay Therapeutics, Inc. (RLAY) has a market capitalisation of $4.17B on NasdaqGM.
What is the P/E ratio of RLAY?
RLAY trades at a trailing price-to-earnings (P/E) ratio of -12.21. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.82.
What is the return on equity (ROE) of RLAY?
RLAY has a return on equity (ROE) of -40.01%. Its return on capital employed (ROCE) is -50.82%.
Is RLAY a good stock to buy?
This page provides a data-driven analysis of Relay Therapeutics, Inc. (RLAY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.